Oss, Netherlands

Carsten Albrecht



Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 146(Granted Patents)


Company Filing History:


Years Active: 2007

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Carsten Albrecht: Innovator in Prodrug Technology

Introduction

Carsten Albrecht is a notable inventor based in Oss, Netherlands. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of prodrugs that can be activated at specific sites within the body. His innovative approach aims to enhance the targeted delivery of therapeutic drugs, especially in the treatment of tumor cells.

Latest Patents

Carsten Albrecht holds a patent for his invention titled "Elongated and multiple spacers in activatible prodrugs." This invention focuses on prodrugs designed to be activated at the preferred site of action, allowing for selective delivery of therapeutic parent drugs to target cells. The prodrugs are characterized by a specific chemical formula that includes elongated self-elimination spacer systems, which play a crucial role in the activation process.

Career Highlights

Throughout his career, Carsten has demonstrated a commitment to advancing drug delivery systems. His work has the potential to significantly improve the efficacy of treatments for various medical conditions, particularly cancer. With a patent portfolio that includes this innovative prodrug technology, he continues to contribute to the pharmaceutical industry.

Collaborations

Carsten collaborates with talented professionals in his field, including Franciscus Marinus Hendrikus De Groot and Patrick Henry Beusker. These partnerships enhance the research and development efforts at Syntarga Bv, where he currently works.

Conclusion

Carsten Albrecht's contributions to prodrug technology exemplify the importance of innovation in the pharmaceutical industry. His work not only advances scientific knowledge but also holds promise for improving patient outcomes through targeted drug delivery.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…